Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation.

Tang AT, Sullivan KR, Hong CC, Goddard LM, Mahadevan A, Ren A, Pardo H, Peiper A, Griffin E, Tanes C, Mattei LM, Yang J, Li L, Mericko-Ishizuka P, Shen L, Hobson N, Girard R, Lightle R, Moore T, Shenkar R, Polster SP, Roedel CJ, Li N, Zhu Q, Whitehead KJ, Zheng X, Akers A, Morrison L, Kim H, Bittinger K, Lengner CJ, Schwaninger M, Velcich A, Augenlicht L, Abdelilah-Seyfried S, Min W, Marchuk DA, Awad IA, Kahn ML.

Sci Transl Med. 2019 Nov 27;11(520). pii: eaaw3521. doi: 10.1126/scitranslmed.aaw3521.

2.

Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites.

Hobson N, Polster SP, Cao Y, Flemming K, Shu Y, Huston J, Gerrard CY, Selwyn R, Mabray M, Zafar A, Girard R, Carrión-Penagos J, Chen YF, Parrish T, Zhou XJ, Koenig JI, Shenkar R, Stadnik A, Koskimäki J, Dimov A, Turley D, Carroll T, Awad IA.

J Magn Reson Imaging. 2019 Sep 12. doi: 10.1002/jmri.26927. [Epub ahead of print]

PMID:
31515878
3.

A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease.

McKerracher L, Shenkar R, Abbinanti M, Cao Y, Peiper A, Liao JK, Lightle R, Moore T, Hobson N, Gallione C, Ruschel J, Koskimäki J, Girard R, Rosen K, Marchuk DA, Awad IA.

Transl Stroke Res. 2019 Aug 24. doi: 10.1007/s12975-019-00725-8. [Epub ahead of print]

PMID:
31446620
4.

Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations.

Koskimäki J, Zhang D, Li Y, Saadat L, Moore T, Lightle R, Polster SP, Carrión-Penagos J, Lyne SB, Zeineddine HA, Shi C, Shenkar R, Romanos S, Avner K, Srinath A, Shen L, Detter MR, Snellings D, Cao Y, Lopez-Ramirez MA, Fonseca G, Tang AT, Faber P, Andrade J, Ginsberg M, Kahn ML, Marchuk DA, Girard R, Awad IA.

Acta Neuropathol Commun. 2019 Aug 19;7(1):132. doi: 10.1186/s40478-019-0789-0.

5.

Biomarkers of cavernous angioma with symptomatic hemorrhage.

Lyne SB, Girard R, Koskimäki J, Zeineddine HA, Zhang D, Cao Y, Li Y, Stadnik A, Moore T, Lightle R, Shi C, Shenkar R, Carrión-Penagos J, Polster SP, Romanos S, Akers A, Lopez-Ramirez M, Whitehead KJ, Kahn ML, Ginsberg MH, Marchuk DA, Awad IA.

JCI Insight. 2019 Jun 20;4(12). pii: 128577. doi: 10.1172/jci.insight.128577. eCollection 2019 Jun 20.

6.

Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive Pdcd10/Ccm3 Disease.

Shenkar R, Peiper A, Pardo H, Moore T, Lightle R, Girard R, Hobson N, Polster SP, Koskimäki J, Zhang D, Lyne SB, Cao Y, Chaudagar K, Saadat L, Gallione C, Pytel P, Liao JK, Marchuk D, Awad IA.

Stroke. 2019 Mar;50(3):738-744. doi: 10.1161/STROKEAHA.118.024058.

PMID:
30744543
7.

Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes.

Koskimäki J, Girard R, Li Y, Saadat L, Zeineddine HA, Lightle R, Moore T, Lyne S, Avner K, Shenkar R, Cao Y, Shi C, Polster SP, Zhang D, Carrión-Penagos J, Romanos S, Fonseca G, Lopez-Ramirez MA, Chapman EM, Popiel E, Tang AT, Akers A, Faber P, Andrade J, Ginsberg M, Derry WB, Kahn ML, Marchuk DA, Awad IA.

JCI Insight. 2019 Feb 7;4(3). pii: 126167. doi: 10.1172/jci.insight.126167. [Epub ahead of print]

8.

Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.

Polster SP, Stadnik A, Akers AL, Cao Y, Christoforidis GA, Fam MD, Flemming KD, Girard R, Hobson N, Koenig JI, Koskimäki J, Lane K, Liao JK, Lee C, Lyne SB, McBee N, Morrison L, Piedad K, Shenkar R, Sorrentino M, Thompson RE, Whitehead KJ, Zeineddine HA, Hanley DF, Awad IA.

Neurosurgery. 2019 Dec 1;85(6):843-853. doi: 10.1093/neuros/nyy539.

PMID:
30476251
9.

Phenotypic characterization of murine models of cerebral cavernous malformations.

Zeineddine HA, Girard R, Saadat L, Shen L, Lightle R, Moore T, Cao Y, Hobson N, Shenkar R, Avner K, Chaudager K, Koskimäki J, Polster SP, Fam MD, Shi C, Lopez-Ramirez MA, Tang AT, Gallione C, Kahn ML, Ginsberg M, Marchuk DA, Awad IA.

Lab Invest. 2019 Mar;99(3):319-330. doi: 10.1038/s41374-018-0030-y. Epub 2018 Jun 26.

10.

Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.

Girard R, Zeineddine HA, Koskimäki J, Fam MD, Cao Y, Shi C, Moore T, Lightle R, Stadnik A, Chaudagar K, Polster S, Shenkar R, Duggan R, Leclerc D, Whitehead KJ, Li DY, Awad IA.

Circ Res. 2018 Jun 8;122(12):1716-1721. doi: 10.1161/CIRCRESAHA.118.312680. Epub 2018 May 2.

11.

Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

Polster SP, Cao Y, Carroll T, Flemming K, Girard R, Hanley D, Hobson N, Kim H, Koenig J, Koskimäki J, Lane K, Majersik JJ, McBee N, Morrison L, Shenkar R, Stadnik A, Thompson RE, Zabramski J, Zeineddine HA, Awad IA.

Neurosurgery. 2019 Apr 1;84(4):954-964. doi: 10.1093/neuros/nyy108.

PMID:
29660039
12.

Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.

Lopez-Ramirez MA, Fonseca G, Zeineddine HA, Girard R, Moore T, Pham A, Cao Y, Shenkar R, de Kreuk BJ, Lagarrigue F, Lawler J, Glass CK, Awad IA, Ginsberg MH.

J Exp Med. 2017 Nov 6;214(11):3331-3346. doi: 10.1084/jem.20171178. Epub 2017 Sep 28.

13.

Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.

Girard R, Zeineddine HA, Fam MD, Mayampurath A, Cao Y, Shi C, Shenkar R, Polster SP, Jesselson M, Duggan R, Mikati AG, Christoforidis G, Andrade J, Whitehead KJ, Li DY, Awad IA.

Transl Stroke Res. 2018 Feb;9(1):34-43. doi: 10.1007/s12975-017-0561-3. Epub 2017 Aug 17.

14.

Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.

Zeineddine HA, Girard R, Cao Y, Hobson N, Fam MD, Stadnik A, Tan H, Shen J, Chaudagar K, Shenkar R, Thompson RE, McBee N, Hanley D, Carroll T, Christoforidis GA, Awad IA.

J Magn Reson Imaging. 2018 Apr;47(4):1133-1138. doi: 10.1002/jmri.25831. Epub 2017 Aug 9.

15.

Endothelial TLR4 and the microbiome drive cerebral cavernous malformations.

Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, Girard R, Zeineddine HA, Lightle R, Moore T, Cao Y, Shenkar R, Chen M, Mericko P, Yang J, Li L, Tanes C, Kobuley D, Võsa U, Whitehead KJ, Li DY, Franke L, Hart B, Schwaninger M, Henao-Mejia J, Morrison L, Kim H, Awad IA, Zheng X, Kahn ML.

Nature. 2017 May 18;545(7654):305-310. doi: 10.1038/nature22075. Epub 2017 May 10.

16.

RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.

Shenkar R, Shi C, Austin C, Moore T, Lightle R, Cao Y, Zhang L, Wu M, Zeineddine HA, Girard R, McDonald DA, Rorrer A, Gallione C, Pytel P, Liao JK, Marchuk DA, Awad IA.

Stroke. 2017 Jan;48(1):187-194. doi: 10.1161/STROKEAHA.116.015013. Epub 2016 Nov 22.

17.

Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.

Girard R, Fam MD, Zeineddine HA, Tan H, Mikati AG, Shi C, Jesselson M, Shenkar R, Wu M, Cao Y, Hobson N, Larsson HBW, Christoforidis GA, Awad IA.

J Neurosurg. 2017 Jul;127(1):102-110. doi: 10.3171/2016.5.JNS16687. Epub 2016 Aug 5.

18.

Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.

Girard R, Zeineddine HA, Orsbon C, Tan H, Moore T, Hobson N, Shenkar R, Lightle R, Shi C, Fam MD, Cao Y, Shen L, Neander AI, Rorrer A, Gallione C, Tang AT, Kahn ML, Marchuk DA, Luo ZX, Awad IA.

J Neurosci Methods. 2016 Sep 15;271:14-24. doi: 10.1016/j.jneumeth.2016.06.021. Epub 2016 Jun 23.

19.

Corrigendum: Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, Arthur JS, Whitehead KJ, Awad IA, Li DY, Zheng X, Kahn ML.

Nature. 2016 Aug 25;536(7617):488. doi: 10.1038/nature18311. Epub 2016 May 25. No abstract available.

PMID:
27281211
20.

B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.

Shi C, Shenkar R, Zeineddine HA, Girard R, Fam MD, Austin C, Moore T, Lightle R, Zhang L, Wu M, Cao Y, Gunel M, Louvi A, Rorrer A, Gallione C, Marchuk DA, Awad IA.

J Neuroimmune Pharmacol. 2016 Jun;11(2):369-77. doi: 10.1007/s11481-016-9670-0. Epub 2016 Apr 16.

21.

Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, Arthur JS, Whitehead KJ, Awad IA, Li DY, Zheng X, Kahn ML.

Nature. 2016 Apr 7;532(7597):122-6. doi: 10.1038/nature17178. Epub 2016 Mar 30. Erratum in: Nature. 2016 May 25;536(7617):488.

22.

Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.

Girard R, Khanna O, Shenkar R, Zhang L, Wu M, Jesselson M, Zeineddine HA, Gangal A, Fam MD, Gibson CC, Whitehead KJ, Li DY, Liao JK, Shi C, Awad IA.

Biomark Med. 2016;10(3):255-64. doi: 10.2217/bmm.15.118. Epub 2016 Feb 9.

23.

Vascular permeability in cerebral cavernous malformations.

Mikati AG, Khanna O, Zhang L, Girard R, Shenkar R, Guo X, Shah A, Larsson HB, Tan H, Li L, Wishnoff MS, Shi C, Christoforidis GA, Awad IA.

J Cereb Blood Flow Metab. 2015 Oct;35(10):1632-9. doi: 10.1038/jcbfm.2015.98. Epub 2015 May 13.

24.

Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.

Shenkar R, Shi C, Rebeiz T, Stockton RA, McDonald DA, Mikati AG, Zhang L, Austin C, Akers AL, Gallione CJ, Rorrer A, Gunel M, Min W, De Souza JM, Lee C, Marchuk DA, Awad IA.

Genet Med. 2015 Mar;17(3):188-196. doi: 10.1038/gim.2014.97. Epub 2014 Aug 14.

25.

Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations.

Shi C, Shenkar R, Kinloch A, Henderson SG, Shaaya M, Chong AS, Clark MR, Awad IA.

J Neuroimmunol. 2014 Jul 15;272(1-2):67-75. doi: 10.1016/j.jneuroim.2014.04.016. Epub 2014 May 10.

PMID:
24864012
26.

Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis.

McDonald DA, Shi C, Shenkar R, Gallione CJ, Akers AL, Li S, De Castro N, Berg MJ, Corcoran DL, Awad IA, Marchuk DA.

Hum Mol Genet. 2014 Aug 15;23(16):4357-70. doi: 10.1093/hmg/ddu153. Epub 2014 Apr 3.

27.

Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping.

Tan H, Liu T, Wu Y, Thacker J, Shenkar R, Mikati AG, Shi C, Dykstra C, Wang Y, Prasad PV, Edelman RR, Awad IA.

Invest Radiol. 2014 Jul;49(7):498-504. doi: 10.1097/RLI.0000000000000043.

28.

Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations.

Mikati AG, Tan H, Shenkar R, Li L, Zhang L, Guo X, Larsson HB, Shi C, Liu T, Wang Y, Shah A, Edelman RR, Christoforidis G, Awad I.

Stroke. 2014 Feb;45(2):598-601. doi: 10.1161/STROKEAHA.113.003548. Epub 2013 Dec 3.

29.

Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease.

McDonald DA, Shi C, Shenkar R, Stockton RA, Liu F, Ginsberg MH, Marchuk DA, Awad IA.

Stroke. 2012 Feb;43(2):571-4. doi: 10.1161/STROKEAHA.111.625467. Epub 2011 Oct 27.

30.

A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease.

McDonald DA, Shenkar R, Shi C, Stockton RA, Akers AL, Kucherlapati MH, Kucherlapati R, Brainer J, Ginsberg MH, Awad IA, Marchuk DA.

Hum Mol Genet. 2011 Jan 15;20(2):211-22. doi: 10.1093/hmg/ddq433. Epub 2010 Oct 11.

31.

Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution.

Yadla S, Jabbour PM, Shenkar R, Shi C, Campbell PG, Awad IA.

Neurosurg Focus. 2010 Sep;29(3):E4. doi: 10.3171/2010.5.FOCUS10121. Review.

32.

Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Stockton RA, Shenkar R, Awad IA, Ginsberg MH.

J Exp Med. 2010 Apr 12;207(4):881-96. doi: 10.1084/jem.20091258. Epub 2010 Mar 22.

33.

Cerebral cavernous malformations: somatic mutations in vascular endothelial cells.

Gault J, Awad IA, Recksiek P, Shenkar R, Breeze R, Handler M, Kleinschmidt-DeMasters BK.

Neurosurgery. 2009 Jul;65(1):138-44; discussion 144-5. doi: 10.1227/01.NEU.0000348049.81121.C1.

34.

Immune response in human cerebral cavernous malformations.

Shi C, Shenkar R, Du H, Duckworth E, Raja H, Batjer HH, Awad IA.

Stroke. 2009 May;40(5):1659-65. doi: 10.1161/STROKEAHA.108.538769. Epub 2009 Mar 12.

35.

Genomics of human intracranial aneurysm wall.

Shi C, Awad IA, Jafari N, Lin S, Du P, Hage ZA, Shenkar R, Getch CC, Bredel M, Batjer HH, Bendok BR.

Stroke. 2009 Apr;40(4):1252-61. doi: 10.1161/STROKEAHA.108.532036. Epub 2009 Feb 19.

PMID:
19228845
36.

Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models.

Shenkar R, Venkatasubramanian PN, Wyrwicz AM, Zhao JC, Shi C, Akers A, Marchuk DA, Awad IA.

Neurosurgery. 2008 Oct;63(4):790-7; discussion 797-8. doi: 10.1227/01.NEU.0000315862.24920.49.

37.

Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions.

Shenkar R, Venkatasubramanian PN, Zhao JC, Batjer HH, Wyrwicz AM, Awad IA.

Neurosurgery. 2008 Oct;63(4):782-9; discussion 789. doi: 10.1227/01.NEU.0000325490.80694.A2.

38.

Concepts and hypotheses: inflammatory hypothesis in the pathogenesis of cerebral cavernous malformations.

Shenkar R, Shi C, Check IJ, Lipton HL, Awad IA.

Neurosurgery. 2007 Oct;61(4):693-702; discussion 702-3. Review.

PMID:
17986930
39.

Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation.

Shi C, Shenkar R, Batjer HH, Check IJ, Awad IA.

J Neurosurg. 2007 Nov;107(5):1023-6.

PMID:
17977276
40.

Cerebral cavernous malformations: clinical insights from genetic studies.

Mindea SA, Yang BP, Shenkar R, Bendok B, Batjer HH, Awad IA.

Neurosurg Focus. 2006 Jul 15;21(1):e1. Review.

PMID:
16859247
41.

Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion.

Gault J, Shenkar R, Recksiek P, Awad IA.

Stroke. 2005 Apr;36(4):872-4. Epub 2005 Feb 17.

PMID:
15718512
42.

Variations in structural protein expression and endothelial cell proliferation in relation to clinical manifestations of cerebral cavernous malformations.

Shenkar R, Sarin H, Awadallah NA, Gault J, Kleinschmidt-DeMasters BK, Awad IA.

Neurosurgery. 2005 Feb;56(2):343-54.

PMID:
15670382
43.

Pathobiology of human cerebrovascular malformations: basic mechanisms and clinical relevance.

Gault J, Sarin H, Awadallah NA, Shenkar R, Awad IA.

Neurosurgery. 2004 Jul;55(1):1-16; discussion 16-7. Review.

PMID:
15214969
44.

On-pump coronary artery bypass surgery activates human myocardial NF-kappaB and increases TNF-alpha in the heart.

Meldrum DR, Partrick DA, Cleveland JC Jr, Shenkar R, Meldrum KK, Raiesdana A, Ayala A, Brown JW, Harken AH.

J Surg Res. 2003 Jun 15;112(2):175-9. Erratum in: J Surg Res. 2003 Dec;115(2):345.

PMID:
12888335
45.

Differential gene expression in human cerebrovascular malformations.

Shenkar R, Elliott JP, Diener K, Gault J, Hu LJ, Cohrs RJ, Phang T, Hunter L, Breeze RE, Awad IA.

Neurosurgery. 2003 Feb;52(2):465-77; discussion 477-8.

46.

Lipopolysaccharide-induced neutrophil gene expression under in vivo or in vitro conditions.

Arcaroli J, Kupfner J, Yum HK, Shenkar R, Park JS, Abraham E.

Chest. 2002 Mar;121(3 Suppl):76S. No abstract available.

PMID:
11893694
47.

Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury.

Yum HK, Arcaroli J, Kupfner J, Shenkar R, Penninger JM, Sasaki T, Yang KY, Park JS, Abraham E.

J Immunol. 2001 Dec 1;167(11):6601-8.

48.

Interactions between CBP, NF-kappaB, and CREB in the lungs after hemorrhage and endotoxemia.

Shenkar R, Yum HK, Arcaroli J, Kupfner J, Abraham E.

Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L418-26.

50.

Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury.

Abraham E, Carmody A, Shenkar R, Arcaroli J.

Am J Physiol Lung Cell Mol Physiol. 2000 Dec;279(6):L1137-45.

Supplemental Content

Loading ...
Support Center